New research has shown that chronic pain can be objectively measured using brain signals, a report in The Conversation said.
According to the report, a team of researchers conducted a study using brain implants capable of recording neural signals over an extended period.
Their aim was to identify reliable markers of chronic pain severity in four patients as they went about their daily lives.
While pain is typically a subjective experience, there is still much to discover about how pain signals are processed in the brain.
Previous studies often relied on artificial settings, and the relationship between acute and chronic pain circuits remained unclear.
To investigate this further, the researchers surgically implanted electrodes in the brains of four patients experiencing post-stroke pain and phantom limb pain.
Neural signals were recorded in specific brain regions associated with planning, expectation, and emotion.
The patients were then asked to report their pain severity levels multiple times a day for up to six months.
Machine learning models were developed to analyse the recorded brain activity signals and predict the patients' self-reported pain intensity scores.
The number of people suffering from addiction is at an all time high, with more people seeking treatment across the USA due to the fentanyl crisis, but new
studies have shown that addiction drugs may not only be able to aid those suffering from the deadly disease, but also aid people suffering from long COVID.
While there has long been research underway to find a cure for the likes of alcoholism and drug addiction, it turns out naltrexone, a drug used in the addiction
treatment space, is helping people who have been suffering from headaches, seizures and fatigue as a result of long COVID.
According to Dr. Paul Valbuena at The River Source, an Arizona drug rehab, naltrexone is typically used by rehab centers and prescribed to patients suffering from
addiction to reduce cravings and the feeling of euphoria associated with substance use disorder, giving patients clarity and focus to concentrate on recovery.
Thanks to a recent report, that has also been revealed to be the case for those suffering with long COVID too, with Lauren Nichols, a long COVID sufferer from Chicago
being prescribed the drug by her doctor.
She found that the drug helped quell her seizures and headaches, alowing her to think clearly and get on with her life as normal. It's been a similar story for other
patients too, and has marked a major breakthrough in the bid to help those who are still suffering in the aftermath of the pandemic.
More than half of people (52%) do not feel confident in treating backache and less than half (44%) uses community pharmacists' advice as their first step on
self-treatable conditions, a self-care attitudes 2022 survey has revealed.
PAGB, the consumer healthcare association, surveyed over 2,000 adults across the UK about their attitudes towards self-care and access to health services.
According to the survey, the public is in favour of self-care but many people lack the confidence and knowledge to care for the most common self-treatable conditions
including backaches, headaches, diarrhoea and constipation.
Four in five respondents (79%) said that people should take more responsibility for their own health and three-quarters (73%) believe that the NHS should make
self-treatment easier.
Behaviours around the current use of pharmacy varied - with less than half (44%) using community pharmacists as their first step in in getting advice on
self-treatable conditions - but longer term attitudes were encouraging, with 69% supporting the idea of GPs being able to make referrals to pharmacists.
Respondents also supported expanding the role of pharmacists so that their skills can be better utilised.
Drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim on Tuesday were spared thousands of US lawsuits claiming that the heartburn drug Zantac caused cancer,
as a judge found the claims were not backed by sound science.
The ruling by US District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens
of thousands of similar cases pending in state courts around the country.
"We are extremely surprised by this miscarriage of justice," and "fully expect" the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint
statement.
A Sanofi spokesperson said the decision "significantly decreases the scope of the litigation potentially by over 50 per cent," with the remaining litigation being
only in state court.
A spokesperson for GSK said the company welcomed the decision and Pfizer said it was pleased by the outcome.
Privately-held German drugmaker Boehringer said in a statement that it looked forward to "continuing our vigorous defense of the remaining cases in state courts."
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door
for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees.
The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on
an ongoing clinical trial involving 4,526 participants.
Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be
used as part of the national vaccination programme.
The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections
in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
NHS Somerset is aiming to grow its referral rate through GP Community Pharmacist Consultation Service (GP CPCS) to between 4,000 to 6,000 patients a month.
Since June 2021 GPs in Somerset have successfully referred around 1,000 patients a month through the Somerset GP Community Pharmacist Consultation Service (GP CPCS)
Currently, 59 of NHS Somerset's 64 GP practices and all of Somerset's 102 community pharmacists are using the Somerset GP CPCS.
NHS Somerset found that providing the right training for GPs and for reception staff and practice managers was key to a smooth rollout and uptake of the service.
As was making sure the technology worked when making referrals from general practice to community pharmacists.
NHS Somerset is using software called Patient Access Connect, which seamlessly integrates with the EMIS Web GP system used in Somerset, to give practices a quick
and easy way to capture the patient information needed to deliver a referral.
There are a lot of different beauty procedures that you can try in order to achieve healthy-looking skin. It's essential to consult with a dermatologist or
other skin care professional to find out which procedures will work best for you, depending on your skin type and concerns. This article will briefly describe some
of the different procedures that are available. Here are some contemporary beauty procedures to consider.
1. SKIN NEEDLING
Skin needling, also known as micro-needling, is a minimally invasive procedure that can be used to improve the overall appearance of your skin. It involves using a
device with fine needles to create tiny punctures on the skin's surface. Additionally, the effects of skin needling can last long after the initial treatment,
making it a popular choice for those looking for a more lasting solution. This helps to stimulate collagen production and can reduce the appearance of wrinkles,
fine lines, scarring, and other skin imperfections. Skin needling can be done independently or with other treatments such as radiofrequency therapy or chemical peels.
It's important to note that skin needling should only be performed by a licensed professional.
2. RADIOFREQUENCY THERAPY
If you're unhappy with the way your skin looks, it may be time to consider a radiofrequency therapy treatment. Radiofrequency therapy uses electromagnetic waves to
heat up the deeper layers of your skin, stimulating collagen production and improving blood circulation. This can help to improve the appearance of wrinkles, fine
lines, and sagging skin. Additionally, radiofrequency therapy can also help to improve the appearance of cellulite and stretch marks. It's a relatively safe and
non-invasive procedure, and there is little to no downtime.
Being accepted and appearing attractive has always been among the most coveted goals in the world, which has given rise to the multibillion-dollar cosmetic
and beauty industry. Fairy stories have been written about everlasting charm, and battles have been waged over attaining beauty. For the most part throughout history,
people have continuously sought ways to improve their features using natural materials, and as technology advanced, they began to use technical methods like light
therapy to accomplish the same goal.
Chains of cosmetic clinics have sprouted up as a result of advances in technology and cosmetic materials, providing a variety of techniques to slow down the aging
process or improve our appearance. So how can you set up your own beauty treatment and plastic surgery clinic to take advantage of this rapidly expanding market?
Here are some pieces of advice!
FIND QUALITY EQUIPMENT
Your success depends on securing the greatest tools available for skin care and plastic surgery. Good quality equipment is a complete solution for distinguishing
yourself from the competition. The initial step would be to locate different vendors. Using criteria like the cost of the equipment and replacement parts, the
vendor's training, the company's reputation, the after-sales services, yearly maintenance, system performance, warranty, and extended warranties, you may narrow
down your list of recommended suppliers. When selecting the appropriate medical supplies and equipment for your clinic, keep your budget in mind.
As a researcher, it is important to communicate your findings to your peers effectively. After all, the whole point of conducting research is to contribute
new knowledge to the field. One way to do this is by presenting your search results in a clear and easy way for others to understand.
USE A VARIETY OF SOURCES
It is always best to use a variety of sources when conducting research. This allows you to get a more well-rounded view of the topic. Additionally, using multiple
sources can help to ensure that your research is more accurate. When you can find different perspectives on the same topic, it allows you to understand the issue
better and make informed decisions.
When it comes to demonstrating your search results to your peers, it is essential to remember that they may not be familiar with all of the same sources that you are.
Therefore, it is helpful to provide a variety of sources for them to review. Doing so will give them a better understanding of the issue and your research findings.
Additionally, they will be able to see how you arrived at your conclusions.
A University College London team of researchers has developed an artificial intelligence (AI) programme that can identify minute brain anomalies that lead to
epileptic seizures.
The algorithm, used in the Multicentre Epilepsy Lesion Detection project (MELD) and which reports locations of abnormalities in cases of drug-resistant focal
cortical dysplasia (FCD) - a major cause of epilepsy - was developed by a multinational team who used more than 1,000 patient MRI scans from 22 international
epilepsy centres.
Brain regions known as FCDs have evolved improperly and frequently lead to drug-resistant epilepsy. Surgery is usually used to treat it, however, finding the
lesions on an MRI is a constant problem for doctors because MRI scans for FCDs can appear normal.
The scientists employed about 300,000 places throughout the brain to quantify cortical properties from the MRI scans, such as how thick or folded the cortex/brain
surface was.
The Pharmaceutical Services Negotiating Committee on Tuesday (June 30) renamed itself as Community Pharmacy England, promising a "strengthened commitment" to
champion and engage with the sector.
"The name Community Pharmacy England better reflects the breadth of work that we do to both represent and support community pharmacies in England. We are their
champion," the pharmacy negotiator said.
Explaining that the rebranding exercise was in line with proposals put forward by the Review Steering Group (RSG), it said the rebrand was part of its Transforming
Pharmacy Representation (TAPR) work and that it would signal the beginning of a "new engagement strategy" to build stronger relationships with pharmacy owners.
"Becoming Community Pharmacy England is much more than a name change or a new logo, it is a driver for cultural change across our organisation.
"Our members want us to be more authoritative, representative, and influential, and rebranding gives us a clearer and stronger voice, helping us to better speak out
for community pharmacy."
In an oral parliamentary debate on community pharmacy held on Monday (20 March), the government was asked for an indication of 'how much it would cost to
make the best use of community pharmacies'.
A number of Peers at the House of Lords spoke out in support of pharmacies, while others asked when would the government address the current crisis in the sector.
Kicking off the session, Baroness Hodgson asked the responding minister, Lord Evans, about recent pharmacy closures as well as underfunding. She asked whether the
government would 'enter into discussions with PSNC to look at introducing a fairly funded pharmacy first service as soon as possible which will help relieve the
work load on GPs'.
The minister responded: "We have already introduced and funded a range of service in community pharmacy that make use of the clinical skills of pharmacy teams… we
continue to discuss with PSNC how the government can best support the sector to provide support to patients."
The House of Lords oral questions session was opened by Baroness Hodgson on behalf of Baroness Cumberlege as follows: "To ask His Majesty's Government what plans
they have for making the best use of community pharmacies".
The Medicines and Healthcare products Regulatory Agency (MHRA) has maintained the prescription-only status of Aquiette 2.5mg Tablets for symptoms of
overactive bladder, following a public consultation and the review of a reclassification application from the manufacturer Maxwellia Ltd.
Aquiette, which contains the active ingredient oxybutynin, is used for the treatment of long-term symptoms of overactive bladder (OAB) in women aged between 18
and 65, such as the urgent need to urinate and frequent urination without pain.
The regulator decided against the reclassification of Aquiette 2.5mg Tablets from a prescription-only medicine (POM) to a pharmacy (P) medicine, concluding that
a medical prescription continues to be required to ensure the safe use of Aquiette.
Since an OAB diagnosis requires medical supervision to ensure that the correct treatment is received, and other health conditions are not overlooked or left untreated,
the MHRA said the decision would ensure that the medication is used safely and appropriately under medical supervision.
"After taking on board the views of the many patients and healthcare professionals who responded, we have decided to refuse the reclassification of Aquiette 2.5mg
Tablets for women with symptoms of overactive bladder (OAB)," Dr Laura Squire, MHRA chief healthcare quality and access officer, said.
Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a
closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health.
A CLOSER LOOK AT DIABETES
Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D).
Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes.
Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin
therapy to manage type 2 diabetes.
GLP-1 RECEPTOR AGONISTS
A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and
slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C
values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea,
weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.
Community pharmacy teams are urged to share their views relating to the new NHS Booking and Referral Standard (BaRS).
"This will ensure that the tool supports the needs of pharmacy team members and their patients," said the Pharmaceutical Services Negotiating Committee (PSNC).
BaRS is an interoperability standard for healthcare IT systems which should enable booking and referral information to be sent to or from care providers, such as
community pharmacies, quickly, safely and in a format useful to clinicians.
"The intentions are that the BaRS IT standard will eventually be available in all care settings. The way the standard could be used in pharmacies is currently being
considered, including the potential for use for referrals from NHS 111 to community pharmacy."
The BaRS team are conducting interviews (usually lasting 30-45 minutes) to hear more the current experiences and the future preferences regarding sending and
receiving referral messages.
The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the
Swiss drugmaker confirmed on Thursday, September 15.
COMCO conducted an early morning raid on the company on Sept. 13, it said in a statement that did not name Novartis, which subsequently said in its own statement
that it was the group under investigation.
"The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by using one of its patents to initiate litigation
proceedings," COMCO said in a statement.
Novartis said COMCO had started an investigation in collaboration with the European Commission into the assertion of a patent in the broader field of dermatology
treatments.
"In connection with this investigation, COMCO representatives visited the company headquarters in Basel," it said.
Many of us know that oral health plays a hugely important role in our general health and wellbeing. We're continuing to see a rise of cosmetic dentistry
such as veneers and teeth whitening[1] but fundamentally, it shouldn't be forgotten that oral health encompasses so much more than aesthetics. Our diets,
the oral hygiene products we are using, and our brushing techniques are all elements that impact our oral health.
It's been hard to miss in the news that there is a dental crisis in the UK, with 'dental deserts' leaving some areas with over 3,000 patients for every NHS
dentist[2]. With oral health being of such importance to our overall health[3], it's only reiterated to us at Haleon that we must continue to promote access
to dental care and understanding of better dental health.
As I've mentioned in previous articles for Pharmacy Business, an understanding of preventative, self-care is hugely beneficial, not just to improve health
inclusivity but to help reduce these current burdens on both healthcare and dentistry professionals. We know that at Haleon, we, and the consumer healthcare
industry as a whole, have a responsibility to empower people to equip themselves with the tools and information to participate in their own and loved ones'
health - and dental health is such an important part of that.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Anastrozole in a new use to prevent the disease.
The off-patent drug has been used as a breast cancer treatment for many years.
Clinical trials have shown that it can reduce the incidence of breast cancer in post-menopausal women with increased risk by almost 50 per cent.
Health Minister Will Quince expressed his happiness on the approval of the drug that can help to prevent this "cruel disease".
He said: "We've already seen the positive effect Anastrozole can have in treating the disease when it has been detected in post-menopausal women and now we
can use it to stop it developing at all in some women.
The American healthcare company, CVS Health, has decided to remove the cold and cough pills containing phenylephrine from the drug stores.
The following decision comes after the health regulator, the US Food and Drug Administration (FDA) determines the decongestant is ineffective towards flu if
taken orally.
However, when ingested in pill or tablet form, this ingredient fails to reach its destination from the stomach to the nasal passages.
CVS Health spokesperson told USA Today, "We are removing a small number of oral decongestant products that contain phenylephrine as the only active ingredient
from CVS Pharmacy stores but will continue offering many other oral cough and cold products to meet consumer needs."
They almost run more than 9,000 stores in the US whereas their rival, Walgreens has not yet taken the step to remove over-the-counter medications from their shelves.
The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission.
UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week.
The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI."
It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments
effectively.
Henceforth, it will provide us with better data on how well new therapies work.
Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."